ATE510014T1 - Mcp-i-bindende nukleinsäuren - Google Patents

Mcp-i-bindende nukleinsäuren

Info

Publication number
ATE510014T1
ATE510014T1 AT07722818T AT07722818T ATE510014T1 AT E510014 T1 ATE510014 T1 AT E510014T1 AT 07722818 T AT07722818 T AT 07722818T AT 07722818 T AT07722818 T AT 07722818T AT E510014 T1 ATE510014 T1 AT E510014T1
Authority
AT
Austria
Prior art keywords
nucleic acids
mcp
binding nucleic
type
nucleic
Prior art date
Application number
AT07722818T
Other languages
English (en)
Inventor
Werner Purschke
Florian Jarosch
Dirk Eulberg
Sven Klussmann
Klaus Buchner
Christian Maasch
Original Assignee
Noxxon Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Noxxon Pharma Ag filed Critical Noxxon Pharma Ag
Application granted granted Critical
Publication of ATE510014T1 publication Critical patent/ATE510014T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/115—Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/566—Immunoassay; Biospecific binding assay; Materials therefor using specific carrier or receptor proteins as ligand binding reagents where possible specific carrier or receptor proteins are classified with their target compounds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/16—Aptamers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
AT07722818T 2006-02-14 2007-02-14 Mcp-i-bindende nukleinsäuren ATE510014T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06002935 2006-02-14
EP06024202 2006-11-22
PCT/EP2007/001294 WO2007093409A2 (en) 2006-02-14 2007-02-14 Mcp-i binding nucleic acids

Publications (1)

Publication Number Publication Date
ATE510014T1 true ATE510014T1 (de) 2011-06-15

Family

ID=38198593

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07722818T ATE510014T1 (de) 2006-02-14 2007-02-14 Mcp-i-bindende nukleinsäuren

Country Status (16)

Country Link
US (4) US8193159B2 (de)
EP (3) EP2365080B1 (de)
JP (1) JP5537812B2 (de)
KR (2) KR101475865B1 (de)
CN (2) CN101415825B (de)
AT (1) ATE510014T1 (de)
AU (1) AU2007214668B2 (de)
BR (1) BRPI0707842B8 (de)
CA (1) CA2638847C (de)
DK (1) DK2135949T3 (de)
ES (1) ES2397803T3 (de)
MX (2) MX351107B (de)
PL (1) PL2135949T3 (de)
PT (1) PT2135949E (de)
RU (1) RU2518330C2 (de)
WO (1) WO2007093409A2 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8367629B2 (en) * 2006-02-14 2013-02-05 Noxxon Pharma Ag MCP-1 binding nucleic acids and use thereof
PL2135949T3 (pl) 2006-02-14 2013-03-29 Noxxon Pharma Ag Kwasy nukleinowe wiążące MCP-1
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
CA2707089A1 (en) * 2007-11-30 2009-06-04 Noxxon Pharma Ag Mcp-1 binding nucleic acids and use thereof
WO2009149921A2 (en) * 2008-06-11 2009-12-17 Bionucleon S.R.L. Inhibition of hrp-3 using modified oligonucleotides
WO2010070394A1 (en) * 2008-12-17 2010-06-24 Universite Pierre Et Marie Curie-Paris Vi Modulators of the cx3cr1 receptor and therapeutic uses thereof
WO2012025251A1 (en) * 2010-08-27 2012-03-01 Noxxon Pharma Ag Nucleic acids for treatment of chronic complications of diabetes
US8465413B2 (en) 2010-11-25 2013-06-18 Coloplast A/S Method of treating Peyronie's disease
DK2872147T3 (da) 2012-07-13 2023-02-20 Wave Life Sciences Ltd Fremgangsmåde til fremstilling af kirale oligonukleotider
EP3065744B1 (de) 2013-11-04 2021-04-21 Noxxon Pharma AG Ein ccl2-antagonist zur behandlung der proteinurie
WO2021178923A1 (en) 2020-03-06 2021-09-10 Drinksavvy, Inc. Devices and methods for detecting a target analyte of interest
WO2023154452A1 (en) 2022-02-11 2023-08-17 Waypoint Bio, Inc. Cellular staining probes for analyte detection

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6011020A (en) 1990-06-11 2000-01-04 Nexstar Pharmaceuticals, Inc. Nucleic acid ligand complexes
US6670321B1 (en) * 1998-12-30 2003-12-30 The Children's Medical Center Corporation Prevention and treatment for retinal ischemia and edema
EP1306382A1 (de) 2001-10-26 2003-05-02 Noxxon Pharma AG Modifizierte L-Nukleinsäure
EP1438321B1 (de) * 2001-10-26 2010-05-26 Noxxon Pharma AG Modifizierte l-nukleinsäure
EP1386972A1 (de) * 2002-08-01 2004-02-04 Noxxon Pharma AG Verfahren und Vorrichtung zum Entwurf einer Nukleinsäure mit einer gewünschten Eigenschaft
EP1530635B1 (de) * 2002-08-01 2011-06-15 Noxxon Pharma AG Ghrelin bindende nukleinsäuren
KR101189555B1 (ko) 2004-02-09 2012-10-16 주프라몰 파렌테랄 콜로이츠 게엠베하 폴리사카라이드 및 폴리뉴클레오티드로부터 접합체를제조하는 방법
EP1732571A4 (de) * 2004-03-05 2009-09-09 Archemix Corp Kontrollierte modulierung der pharmakokinetik und bioverteilung von aptamer-therapeutika
US20080299130A1 (en) 2004-05-04 2008-12-04 University Of Kentucky Research Foundation Methods And Compositions For The Treatment Of Ocular Neovascularization
US8367629B2 (en) * 2006-02-14 2013-02-05 Noxxon Pharma Ag MCP-1 binding nucleic acids and use thereof
PL2135949T3 (pl) 2006-02-14 2013-03-29 Noxxon Pharma Ag Kwasy nukleinowe wiążące MCP-1
PT2190991T (pt) * 2007-08-06 2019-12-16 Noxxon Pharma Ag Ácidos nucleicos que se ligam a sdf 1 e a sua utilização
CA2707089A1 (en) 2007-11-30 2009-06-04 Noxxon Pharma Ag Mcp-1 binding nucleic acids and use thereof

Also Published As

Publication number Publication date
JP5537812B2 (ja) 2014-07-02
CA2638847A1 (en) 2007-08-23
EP2135949B1 (de) 2012-10-17
CN101415825B (zh) 2013-05-08
US20180066265A1 (en) 2018-03-08
ES2397803T3 (es) 2013-03-11
CN103275984A (zh) 2013-09-04
MX337801B (es) 2016-03-18
WO2007093409A3 (en) 2007-12-13
US10273480B2 (en) 2019-04-30
EP1984501A2 (de) 2008-10-29
EP2365080B1 (de) 2016-04-13
BRPI0707842A2 (pt) 2011-05-10
AU2007214668A1 (en) 2007-08-23
DK2135949T3 (da) 2013-02-04
BRPI0707842B1 (pt) 2021-09-21
RU2518330C2 (ru) 2014-06-10
WO2007093409A2 (en) 2007-08-23
RU2008136907A (ru) 2010-03-20
KR20080105078A (ko) 2008-12-03
US20100284961A1 (en) 2010-11-11
EP2135949A1 (de) 2009-12-23
US20160208262A1 (en) 2016-07-21
CA2638847C (en) 2016-08-09
EP2365080A1 (de) 2011-09-14
CN101415825A (zh) 2009-04-22
WO2007093409A8 (en) 2011-01-20
BRPI0707842B8 (pt) 2023-04-18
PL2135949T3 (pl) 2013-03-29
KR101475865B1 (ko) 2015-01-02
US20130035376A1 (en) 2013-02-07
US8193159B2 (en) 2012-06-05
HK1129127A1 (en) 2009-11-20
EP1984501B1 (de) 2011-05-18
US8691784B2 (en) 2014-04-08
KR101572893B1 (ko) 2015-12-02
PT2135949E (pt) 2013-01-07
AU2007214668B2 (en) 2012-05-24
KR20130100213A (ko) 2013-09-09
JP2009526532A (ja) 2009-07-23
US9670491B2 (en) 2017-06-06
MX351107B (es) 2017-10-02

Similar Documents

Publication Publication Date Title
DK2135949T3 (da) MCP-1-bindende nukleinsyrer
MX2009000656A (es) Acidos nucleicos que se fijan a sdf-i.
MX2010003109A (es) Acidos nucleicos de enlace c5a.
EP2207896A4 (de) Nukleinsäureamplifikation
ES2688623T3 (es) Proteínas de fusión que se unen a factores de crecimiento
WO2008146745A1 (ja) 新規なリゾホスファチジン酸アシル基転移酵素遺伝子
MX346862B (es) Secuencias consenso de envoltura de vih y método para usar las mismas.
DK2066684T3 (da) 5´-Modificerede bicycliske nukleinsyreanaloge
EP2097111A4 (de) Heterodimere von glutaminsäure
DK2228440T3 (da) Varianter af beta-glucosidaser
EP2162555A4 (de) Spezifische amplifizierung von tumorspezifischen dna-sequenzen
WO2007062160A8 (en) Methods and compositions for sequencing a nucleic acid
EP3586868A3 (de) Leberspezifische nukleinsäureregulatorische elemente sowie verfahren und verwendung davon
EP2320913A4 (de) Nukleinsäureaptamere
WO2008109142A3 (en) Pirna and uses related thereto
EP2152883A4 (de) Rekombinante bakterien mit vektoren zur expression von nukleinsäuresequenzencodierenden antigenen
EP2169057A4 (de) In milchsäurebakterium entstandene doppelstrang-rna
MX2010001490A (es) Acidos nucleicos de enlace sdf-1 y uso de los mismos.
MX2009000654A (es) Medios para inhibir la expresion de la cinasa de proteina 3.
ATE541944T1 (de) Polynukleotidprimer
ATE536360T1 (de) Neues nukleinsäuretransfersystem
WO2009111440A3 (en) Methods and compositions for reducing nucleotide impurities
EP2247728A4 (de) Selektion von rna-aptameren als mittel gegen malaria
ATE513041T1 (de) Ghrelin bindende nukleinsäuren
EP2098594A4 (de) Nukleinsäuremolekül mit fähigkeit zur bindung an aus kaninchen stammenden igg-antikörper

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties